# Vivek Gupta

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4128424/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 74 papers | 4,000 citations | 109264 35 h-index | 118793 62 g-index |
| 74 all docs | 74 docs citations | 74 times ranked | 5949 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. Drug Delivery and Translational Research, 2022, 12, 2474-2487. | 3.0 | 15 |
| 2 | Particle shape engineering for improving safety and efficacy of doxorubicin â€" A case study of rod-shaped carriers in resistant small cell lung cancer. , 2022, 137, 212850. | | 6 |
| 3 | Repurposing therapeutics for malignant pleural mesothelioma (MPM) â€" Updates on clinical translations and future outlook. Life Sciences, 2022, 304, 120716. | 2.0 | 3 |
| 4 | Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 8975-8997. | 2.9 | 6 |
| 5 | Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)â€"development and in-vitro efficacy. Drug Delivery and Translational Research, 2021, 11, 927-943. | 3.0 | 34 |
| 6 | Therapeutic potential of inhalable medications to combat coronavirus disease-2019. Therapeutic Delivery, 2021, 12, 105-110. | 1.2 | 6 |
| 7 | Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation â€" Evaluation of intestinal absorption and anti-cancer activity. Journal of Molecular Liquids, 2021, 327, 114866. | 2.3 | 12 |
| 8 | Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics â€" Evaluation in biologically relevant in-vitro models. Materials Science and Engineering C, 2021, 121, 111891. | 3.8 | 9 |
| 9 | Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes. International Journal of Molecular Sciences, 2021, 22, 4783. | 1.8 | 20 |
| 10 | Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs. Materials Science and Engineering C, 2021, 128, 112324. | 3.8 | 7 |
| 11 | Development and characterization of inhalable transferrin functionalized amodiaquine nanoparticles â€" Efficacy in Non-Small Cell Lung Cancer (NSCLC) treatment. International Journal of Pharmaceutics, 2021, 608, 121038. | 2.6 | 8 |
| 12 | Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. International Journal of Molecular Sciences, 2020, 21, 7575. | 1.8 | 44 |
| 13 | The preparation of lipid-based drug delivery system using melt extrusion. Drug Discovery Today, 2020, 25, 1930-1943. | 3.2 | 15 |
| 14 | Utilizing drug repurposing against COVID-19 â€" Efficacy, limitations, and challenges. Life Sciences, 2020, 259, 118275. | 2.0 | 89 |
| 15 | Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer. International Journal of Biological Macromolecules, 2020, 164, 638-650. | 3.6 | 60 |
| 16 | Enhanced solubility, stability, permeation and anti-cancer efficacy of Celastrol-Î²-cyclodextrin inclusion complex. Journal of Molecular Liquids, 2020, 318, 113936. | 2.3 | 38 |
| 17 | Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation. International Journal of Molecular Sciences, 2020, 21, 6306. | 1.8 | 12 |
| 18 | Development of pharmaceutically scalable inhaled anti-cancer nanotherapy â€" Repurposing amodiaquine for non-small cell lung cancer (NSCLC). Materials Science and Engineering C, 2020, 115, 111139. | 3.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research, 2020, 37, 123. | 1.7 | 14 |
| 20 | Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer. Pharmaceutical Research, 2020, 37, 67. | 1.7 | 40 |
| 21 | Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. Pharmaceutics, 2020, 12, 206. | 2.0 | 53 |
| 22 | Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127372. | 1.0 | 7 |
| 23 | Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrolâ€"Applications in Non-small Cell Lung Cancer Treatment. AAPS PharmSciTech, 2020, 21, 183. | 1.5 | 26 |
| 24 | Analytical challenges and advancements in bioanalysis of therapeutic proteins. Bioanalysis, 2020, 12, 207-209. | 0.6 | 1 |
| 25 | Statistical optimization and validation of a novel ultra-performance liquid chromatography method for estimation of nintedanib in rat and human plasma. Bioanalysis, 2020, 12, 159-174. | 0.6 | 8 |
| 26 | Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective. Therapeutic Delivery, 2020, 11, 213-215. | 1.2 | 5 |
| 27 | Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. International Journal of Pharmaceutics, 2020, 577, 118995. | 2.6 | 53 |
| 28 | Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma â€“ A rare thoracic cancer. International Journal of Biological Macromolecules, 2020, 160, 128-141. | 3.6 | 27 |
| 29 | Current Status and Perspectives in Mucosal Drug Delivery of Nanotherapeutic Systems. AAPS Advances in the Pharmaceutical Sciences Series, 2020, , 83-106. | 0.2 | 0 |
| 30 | Metformin-Encapsulated Liposome Delivery System: An Effective Treatment Approach against Breast Cancer. Pharmaceutics, 2019, 11, 559. | 2.0 | 53 |
| 31 | Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). , 2019, , . | | 0 |
| 32 | Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discovery Today, 2019, 24, 2076-2085. | 3.2 | 239 |
| 33 | Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. European Journal of Pharmaceutical Sciences, 2019, 133, 145-159. | 1.9 | 44 |
| 34 | Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis. Journal of Drug Delivery Science and Technology, 2019, 49, 352-364. | 1.4 | 41 |
| 35 | Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 197-237. | 0.4 | 0 |
| 36 | Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. International Journal of Biological Macromolecules, 2019, 122, 338-347. | 3.6 | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability. Carbohydrate Polymers, 2019, 204, 68-77. | 5.1 | 47 |
| 38 | Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nature Nanotechnology, 2017, 12, 589-594. | 15.6 | 154 |
| 39 | Advances in treatment of pulmonary arterial hypertension: patent review. Expert Opinion on Therapeutic Patents, 2017, 27, 907-918. | 2.4 | 13 |
| 40 | Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. AAPS Journal, 2017, 19, 1669-1681. | 2.2 | 57 |
| 41 | Bioadhesive Polymers for Targeted Drug Delivery. , 2017, , 322-362. | | 4 |
| 42 | Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective. Current Medicinal Chemistry, 2017, 24, 2439-2458. | 1.2 | 6 |
| 43 | Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions. Chest, 2016, 150, 1186A. | 0.4 | 0 |
| 44 | Microfluidicsâ€based 3D cell culture models: Utility in novel drug discovery and delivery research. Bioengineering and Translational Medicine, 2016, 1, 63-81. | 3.9 | 167 |
| 45 | Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices. Annals of Biomedical Engineering, 2016, 44, 1993-2007. | 1.3 | 44 |
| 46 | The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells. PLoS ONE, 2016, 11, e0152074. | 1.1 | 90 |
| 47 | Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Scientific Reports, 2015, 5, 13476. | 1.6 | 38 |
| 48 | Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 0.9 | 1 |
| 49 | Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. Journal of Controlled Release, 2015, 211, 118-133. | 4.8 | 36 |
| 50 | Topical delivery of Cyclosporine A into the skin using SPACE-peptide. Journal of Controlled Release, 2015, 199, 190-197. | 4.8 | 37 |
| 51 | Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches. Biomaterials, 2015, 68, 1-8. | 5.7 | 76 |
| 52 | Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation. Journal of Controlled Release, 2015, 199, 29-36. | 4.8 | 130 |
| 53 | Exosomes: Natural Carriers for siRNA Delivery. Current Pharmaceutical Design, 2015, 21, 4556-4565. | 0.9 | 35 |
| 54 | Topical delivery of siRNA into skin using SPACE-peptide carriers. Journal of Controlled Release, 2014, 179, 33-41. | 4.8 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers. Journal of Controlled Release, 2014, 173, 67-74. | 4.8 | 100 |
| 56 | In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. European Journal of Pharmaceutical Sciences, 2013, 49, 805-818. | 1.9 | 121 |
| 57 | Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. Journal of Controlled Release, 2013, 167, 189-199. | 4.8 | 105 |
| 58 | Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. Journal of Controlled Release, 2013, 172, 753-762. | 4.8 | 69 |
| 59 | Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells. ACS Nano, 2013, 7, 11129-11137. | 7.3 | 276 |
| 60 | Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10753-10758. | 3.3 | 554 |
| 61 | A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. Journal of Controlled Release, 2013, 172, 541-549. | 4.8 | 64 |
| 62 | Inhaled PLGA Particles of Prostaglandin E<sub>1</sub> Ameliorate Symptoms and Progression of Pulmonary Hypertension at a Reduced Dosing Frequency. Molecular Pharmaceutics, 2013, 10, 1655-1667. | 2.3 | 25 |
| 63 | Permeation of Insulin, Calcitonin and Exenatide across Caco-2 Monolayers: Measurement Using a Rapid, 3-Day System. PLoS ONE, 2013, 8, e57136. | 1.1 | 42 |
| 64 | Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L733-L747. | 1.3 | 18 |
| 65 | PEGâ€“PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. Journal of Controlled Release, 2012, 162, 310-320. | 4.8 | 124 |
| 66 | PLGA Microparticles Encapsulating Prostaglandin E1-Hydroxypropyl-Î²-cyclodextrin (PGE1-HPÎ²CD) Complex for the Treatment of Pulmonary Arterial Hypertension (PAH). Pharmaceutical Research, 2011, 28, 1733-1749. | 1.7 | 48 |
| 67 | Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. International Journal of Pharmaceutics, 2011, 413, 51-62. | 2.6 | 48 |
| 68 | Inhalational Therapy for Pulmonary Arterial Hypertension: Current Status and Future Prospects. Critical Reviews in Therapeutic Drug Carrier Systems, 2010, 27, 313-370. | 1.2 | 24 |
| 69 | Particle Size Influences the Immune Response Produced by Hepatitis B Vaccine Formulated in Inhalable Particles. Pharmaceutical Research, 2010, 27, 905-919. | 1.7 | 72 |
| 70 | Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. Journal of Pharmaceutical Sciences, 2010, 99, 1774-1789. | 1.6 | 29 |
| 71 | Inhalable Lactose-Based Dry Powder Formulations of Low Molecular Weight Heparin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 97-104. | 0.7 | 25 |
| 72 | Principles and Practice of Pulmonary Drug Delivery. , 2010, , 371-419. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. European Journal of Pharmaceutical Sciences, 2009, 38, 165-171. | 1.9 | 37 |
| 74 | Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. International Journal of Pharmaceutics, 2009, 379, 41-50. | 2.6 | 74 |